Atossa Therapeutics, Inc.
NASDAQ:ATOS
0.96 (USD) • At close January 6, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Atossa Therapeutics, Inc. |
Symbool | ATOS |
Munteenheid | USD |
Prijs | 0.96 |
Beurswaarde | 120,806,700 |
Dividendpercentage | 0% |
52-weken bereik | 0.77 - 2.31 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Steven C. Quay FCAP, M.D., Ph.D. |
Website | https://www.atossatherapeutics.com |
An error occurred while fetching data.
Over Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)